Guidelines for TMS/tES clinical services and research through the COVID-19 pandemic

Marom Bikson; Colleen A. Hanlon; Adam J. Woods; Bernadette T. Gillick; Leigh Charvet; Claus Lamm; Graziella Madeo; Adrienn Holczer; Jorge Almeida; Andrea Antal; Mohammad Reza Ay; Chris Baeken; Daniel M. Blumberger; Salvatore Campanella; Joan A. Camprodon; Lasse Christiansen; Colleen Loo; Jennifer T. Crinion; Paul Fitzgerald; Luigi Gallimberti; Peyman Ghobadi-Azbari; Iman Ghodratitoostani; Roland H. Grabner; Gesa Hartwigsen; Akimasa Hirata; Adam Kirton; Helena Knotkova; Evgeny Krupitsky; Paola Marangolo; Ester M. Nakamura-Palacios; Weronika Potok; Samir K. Praharaj; Christian C. Ruff; Gottfried Schlaug; Hartwig R. Siebner; Charlotte J. Stagg; Axel Thielscher; Nicole Wenderoth; Ti Fei Yuan; Xiaochu Zhang; Hamed Ekhtiari

doi:10.1016/j.brs.2020.05.010

Guidelines for TMS/tES clinical services and research through the COVID-19 pandemic

Marom Bikson, Colleen A. Hanlon, Adam J. Woods, Bernadette T. Gillick, Leigh Charvet, Claus Lamm, Graziella Madeo, Adrienn Holczer, Jorge Almeida, Andrea Antal, Mohammad Reza Ay, Chris Baeken, Daniel M. Blumberger, Salvatore Campanella, Joan A. Camprodon, Lasse Christiansen, Colleen Loo, Jennifer T. Crinion, Paul Fitzgerald, Luigi GallimbertiPeyman Ghobadi-Azbari, Iman Ghodratitoostani, Roland H. Grabner, Gesa Hartwigsen, Akimasa Hirata, Adam Kirton, Helena Knotkova, Evgeny Krupitsky, Paola Marangolo, Ester M. Nakamura-Palacios, Weronika Potok, Samir K. Praharaj, Christian C. Ruff, Gottfried Schlaug, Hartwig R. Siebner, Charlotte J. Stagg, Axel Thielscher, Nicole Wenderoth, Ti Fei Yuan, Xiaochu Zhang, Hamed Ekhtiari

Physical Therapy

Research output: Contribution to journal › Article › peer-review

67 Scopus citations

Abstract

Background: The COVID-19 pandemic has broadly disrupted biomedical treatment and research including non-invasive brain stimulation (NIBS). Moreover, the rapid onset of societal disruption and evolving regulatory restrictions may not have allowed for systematic planning of how clinical and research work may continue throughout the pandemic or be restarted as restrictions are abated. The urgency to provide and develop NIBS as an intervention for diverse neurological and mental health indications, and as a catalyst of fundamental brain research, is not dampened by the parallel efforts to address the most life-threatening aspects of COVID-19; rather in many cases the need for NIBS is heightened including the potential to mitigate mental health consequences related to COVID-19. Objective: To facilitate the re-establishment of access to NIBS clinical services and research operations during the current COVID-19 pandemic and possible future outbreaks, we develop and discuss a framework for balancing the importance of NIBS operations with safety considerations, while addressing the needs of all stakeholders. We focus on Transcranial Magnetic Stimulation (TMS) and low intensity transcranial Electrical Stimulation (tES) - including transcranial Direct Current Stimulation (tDCS) and transcranial Alternating Current Stimulation (tACS). Methods: The present consensus paper provides guidelines and good practices for managing and reopening NIBS clinics and laboratories through the immediate and ongoing stages of COVID-19. The document reflects the analysis of experts with domain-relevant expertise spanning NIBS technology, clinical services, and basic and clinical research – with an international perspective. We outline regulatory aspects, human resources, NIBS optimization, as well as accommodations for specific demographics. Results: A model based on three phases (early COVID-19 impact, current practices, and future preparation) with an 11-step checklist (spanning removing or streamlining in-person protocols, incorporating telemedicine, and addressing COVID-19-associated adverse events) is proposed. Recommendations on implementing social distancing and sterilization of NIBS related equipment, specific considerations of COVID-19 positive populations including mental health comorbidities, as well as considerations regarding regulatory and human resource in the era of COVID-19 are outlined. We discuss COVID-19 considerations specifically for clinical (sub-)populations including pediatric, stroke, addiction, and the elderly. Numerous case-examples across the world are described. Conclusion: There is an evident, and in cases urgent, need to maintain NIBS operations through the COVID-19 pandemic, including anticipating future pandemic waves and addressing effects of COVID-19 on brain and mind. The proposed robust and structured strategy aims to address the current and anticipated future challenges while maintaining scientific rigor and managing risk.

Original language	English (US)
Pages (from-to)	1124-1149
Number of pages	26
Journal	Brain Stimulation
Volume	13
Issue number	4
DOIs	https://doi.org/10.1016/j.brs.2020.05.010
State	Published - May 16 2020

Bibliographical note

Funding Information:
Marom Bikson has equity on Soterix Medical, is consultant or SAB of Boston Scientific, GSK, Halo Neuroscience, GSK, X and is inventor of brain stimulation patents and has grant support from NIH (MH111896, NS101362, NS112996). Colleen A. Hanlon has served as a consultant for Brainsway and receives grant support from the NIH (R01DA036617, R01DA044471, R01AA027705, R21DA044503). Adam J. Woods is a member of the scientific advisory board for Halo Neuroscience and has grant support from NIH (R01AG054077, R01AG064587, K01AG050707, R21MH112206, R37AG033906, RF1MH114290). Bernadette T. Gillick reports no conflict of interest and has current grant support from the NIH (R21HD097575), the National Center of Neuromodulation for Rehabilitation, and the Shepherd Trust/Jensen Family Award. Leigh Charvet has no conflict of interest and has current grant support from the NIH (R21NS101712), US Department of Defense (W81XWH-17-1-0320), National Multiple Sclerosis Society (RG-1803-30492) and the Lourie Foundation Inc. Adrienn Holczer reports no conflict of interest and is supported by the grant EFOP 3.6.3-VEKOP-16-2017-00009. Jorge Almeida has no conflict of interest and is supported by an ERC Starting Grant (Grant # 802553 - “ContentMAP”), and by grant PTDC/MHC-PCN/6805/2014 from Fundação para a Ciência e a Tecnologia Portugal, and Programa COMPETE. Andrea Antal has received honoraria as speaker from NeuroCare (Munich, Germany) and as consultant from Savir GmbH (Magdeburg, Germany). Daniel M. Blumberger has received research support from Canadian Institutes for Health Research, National Institutes Health (US), Brain Canada and the Temerty Family through the CAMH Foundation and the Campbell Family Research Institute. He received research support and in-kind equipment support for an investigator-initiated study from Brainsway Ltd. He is the site principal investigator for three sponsor-initiated studies for Brainsway Ltd. He also receives in-kind equipment support from Magventure for investigator-initiated research. He received medication supplies for an investigator-initiated trial from Indivior. Joan A. Camprodon is a scientific advisor for Apex Neuroscience, has received royalties as book editor from Springer and has grant support from NIH (RO1 MH112737, R21 DA042271, R21 AG056958 and R21 MH115280). Colleen Loo has received royalties as book editor from Springer and has grant support from the Australian National Health and Medical Research Council. Jenny Crinion declares no conflict of interest and is supported by a Wellcome Trust Senior Research Fellowship in Clinical Science (106161/Z/14/Z). For this research as a part of Multidisciplinary Cognitive Rehabilitation (MCR) Platform, Iman Ghodratitoostani was supported (Grant number: 2013/07375-0) by Innovation and Diffusion of Mathematical Sciences Center Applied to Industry (CEPID-CeMEAI) of Sao Paulo Research Foundation (FAPESP), the University of Sao Paulo. Roland H. Grabner reports no conflict of interest and is supported by the Austrian Science Fund FWF (Grant P30050). Christian Ruff reports no conflict of interest and was supported by grants from the Swiss National Science Foundation SNSF (grant no. 100019L_173248) and from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme (grant agreement No 725355, ERC Consolidator BRAINCODES). Gottfried Schlaug has no conflict of interest and acknowledges support from the NIH (R01MH111874, U01NS102353). Hartwig R. Siebner has received honoraria as speaker from Sanofi Genzyme, Denmark and Novartis, Denmark, as consultant from Sanofi Genzyme, Denmark and as editor-in-chief (Neuroimage Clinical) and senior editor (NeuroImage) from Elsevier Publishers, Amsterdam, The Netherlands. He has received royalties as book editor from Springer Publishers, Stuttgart, Germany and from Gyldendal Publishers, Copenhagen, Denmark. Hartwig R. Siebner holds a 5-year professorship in precision medicine at the Faculty of Health Sciences and Medicine, University of Copenhagen which is sponsored by the Lundbeck Foundation (Grant Nr. R186-2015-2138). Xiaochu Zhang reports no conflict of interest and is supported by The National Key Basic Research Program (2016YFA0400900 and 2018YFC0831101), The National Natural Science Foundation of China (71942003, 31771221, 61773360, and 71874170). Hamed Ekhtiari reported no conflict of interest and is supported by grants from Brain and Behavior Foundation (NARSAD Young Investigator Award #27305) and Warren K. Family Foundation. Claus Lamm, Graziella Madeo, Mohammad Reza Ay, Chris Baeken, Salvatore Campanella, Lasse Christiansen, Paul Fitzgerald, Luigi Gallimberti, Peyman Ghobadi-Azbari, Gesa Hartwigsen, Akimasa Hirata, Adam Kirton, Helena Knotkova, Evgeny Krupitsky, Paola Marangolo, Ester M. Nakamura-Palacios, Weronika Potok, Samir K. Praharaj, Charlotte J. Stagg, Axel Thielscher, Nicole Wenderoth, and Ti-Fei Yuan report no conflict of interest or specific funding for this work.

Funding Information:
In most places across the world, neuromodulation studies have been suspended, yet the costs associated with those experiments (e.g. salaries, animal housing and food costs) have continued. This placed a financial burden on these studies and will also delay the final results of the studies. Thankfully, several funding agencies, including the US National Institute of Health, Wellcome Trust and the Medical Research Council UK, and Swiss National Science Foundation have announced the ability to apply for an Administrative or grant Supplement to cover unforeseen COVID-19-related costs. They have also streamlined the process for getting approval for a No Cost Extension. These steps offer significant relief to researchers and increase the likelihood that the dedicated resources already invested in these projects will be fruitful.

Publisher Copyright:
© 2020 The Authors

Keywords

COVID-19
Non-invasive brain stimulation
Transcranial alternating current stimulation
Transcranial direct current stimulation
Transcranial electrical stimulation
Transcranial magnetic stimulation
Pandemics
Humans
Behavior, Addictive/therapy
Coronavirus Infections/epidemiology
SARS-CoV-2
Pneumonia, Viral/epidemiology
Stroke/therapy
Betacoronavirus
Child
Transcranial Direct Current Stimulation/methods
Brain/physiology
Biomedical Research/methods
Clinical Trials as Topic
Transcranial Magnetic Stimulation/methods
Nervous System Diseases/therapy
Telemedicine/methods
Delivery of Health Care/methods
Substance-Related Disorders/therapy
Aged
Practice Guidelines as Topic

PubMed: MeSH publication types

Journal Article

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Publisher link

10.1016/j.brs.2020.05.010

Find It

Find It at U of M Libraries

Cite this

Bikson, M., Hanlon, C. A., Woods, A. J., Gillick, B. T., Charvet, L., Lamm, C., Madeo, G., Holczer, A., Almeida, J., Antal, A., Ay, M. R., Baeken, C., Blumberger, D. M., Campanella, S., Camprodon, J. A., Christiansen, L., Loo, C., Crinion, J. T., Fitzgerald, P., ... Ekhtiari, H. (2020). Guidelines for TMS/tES clinical services and research through the COVID-19 pandemic. Brain Stimulation, 13(4), 1124-1149. https://doi.org/10.1016/j.brs.2020.05.010

Bikson, M, Hanlon, CA, Woods, AJ, Gillick, BT, Charvet, L, Lamm, C, Madeo, G, Holczer, A, Almeida, J, Antal, A, Ay, MR, Baeken, C, Blumberger, DM, Campanella, S, Camprodon, JA, Christiansen, L, Loo, C, Crinion, JT, Fitzgerald, P, Gallimberti, L, Ghobadi-Azbari, P, Ghodratitoostani, I, Grabner, RH, Hartwigsen, G, Hirata, A, Kirton, A, Knotkova, H, Krupitsky, E, Marangolo, P, Nakamura-Palacios, EM, Potok, W, Praharaj, SK, Ruff, CC, Schlaug, G, Siebner, HR, Stagg, CJ, Thielscher, A, Wenderoth, N, Yuan, TF, Zhang, X & Ekhtiari, H 2020, 'Guidelines for TMS/tES clinical services and research through the COVID-19 pandemic', Brain Stimulation, vol. 13, no. 4, pp. 1124-1149. https://doi.org/10.1016/j.brs.2020.05.010

@article{73c1ff46352848959fac24beb8d8d926,

title = "Guidelines for TMS/tES clinical services and research through the COVID-19 pandemic",

abstract = "Background: The COVID-19 pandemic has broadly disrupted biomedical treatment and research including non-invasive brain stimulation (NIBS). Moreover, the rapid onset of societal disruption and evolving regulatory restrictions may not have allowed for systematic planning of how clinical and research work may continue throughout the pandemic or be restarted as restrictions are abated. The urgency to provide and develop NIBS as an intervention for diverse neurological and mental health indications, and as a catalyst of fundamental brain research, is not dampened by the parallel efforts to address the most life-threatening aspects of COVID-19; rather in many cases the need for NIBS is heightened including the potential to mitigate mental health consequences related to COVID-19. Objective: To facilitate the re-establishment of access to NIBS clinical services and research operations during the current COVID-19 pandemic and possible future outbreaks, we develop and discuss a framework for balancing the importance of NIBS operations with safety considerations, while addressing the needs of all stakeholders. We focus on Transcranial Magnetic Stimulation (TMS) and low intensity transcranial Electrical Stimulation (tES) - including transcranial Direct Current Stimulation (tDCS) and transcranial Alternating Current Stimulation (tACS). Methods: The present consensus paper provides guidelines and good practices for managing and reopening NIBS clinics and laboratories through the immediate and ongoing stages of COVID-19. The document reflects the analysis of experts with domain-relevant expertise spanning NIBS technology, clinical services, and basic and clinical research – with an international perspective. We outline regulatory aspects, human resources, NIBS optimization, as well as accommodations for specific demographics. Results: A model based on three phases (early COVID-19 impact, current practices, and future preparation) with an 11-step checklist (spanning removing or streamlining in-person protocols, incorporating telemedicine, and addressing COVID-19-associated adverse events) is proposed. Recommendations on implementing social distancing and sterilization of NIBS related equipment, specific considerations of COVID-19 positive populations including mental health comorbidities, as well as considerations regarding regulatory and human resource in the era of COVID-19 are outlined. We discuss COVID-19 considerations specifically for clinical (sub-)populations including pediatric, stroke, addiction, and the elderly. Numerous case-examples across the world are described. Conclusion: There is an evident, and in cases urgent, need to maintain NIBS operations through the COVID-19 pandemic, including anticipating future pandemic waves and addressing effects of COVID-19 on brain and mind. The proposed robust and structured strategy aims to address the current and anticipated future challenges while maintaining scientific rigor and managing risk.",

keywords = "COVID-19, Non-invasive brain stimulation, Transcranial alternating current stimulation, Transcranial direct current stimulation, Transcranial electrical stimulation, Transcranial magnetic stimulation, Pandemics, Humans, Behavior, Addictive/therapy, Coronavirus Infections/epidemiology, SARS-CoV-2, Pneumonia, Viral/epidemiology, Stroke/therapy, Betacoronavirus, Child, Transcranial Direct Current Stimulation/methods, Brain/physiology, Biomedical Research/methods, Clinical Trials as Topic, Transcranial Magnetic Stimulation/methods, Nervous System Diseases/therapy, Telemedicine/methods, Delivery of Health Care/methods, Substance-Related Disorders/therapy, Aged, Practice Guidelines as Topic",

author = "Marom Bikson and Hanlon, {Colleen A.} and Woods, {Adam J.} and Gillick, {Bernadette T.} and Leigh Charvet and Claus Lamm and Graziella Madeo and Adrienn Holczer and Jorge Almeida and Andrea Antal and Ay, {Mohammad Reza} and Chris Baeken and Blumberger, {Daniel M.} and Salvatore Campanella and Camprodon, {Joan A.} and Lasse Christiansen and Colleen Loo and Crinion, {Jennifer T.} and Paul Fitzgerald and Luigi Gallimberti and Peyman Ghobadi-Azbari and Iman Ghodratitoostani and Grabner, {Roland H.} and Gesa Hartwigsen and Akimasa Hirata and Adam Kirton and Helena Knotkova and Evgeny Krupitsky and Paola Marangolo and Nakamura-Palacios, {Ester M.} and Weronika Potok and Praharaj, {Samir K.} and Ruff, {Christian C.} and Gottfried Schlaug and Siebner, {Hartwig R.} and Stagg, {Charlotte J.} and Axel Thielscher and Nicole Wenderoth and Yuan, {Ti Fei} and Xiaochu Zhang and Hamed Ekhtiari",

note = "Funding Information: Marom Bikson has equity on Soterix Medical, is consultant or SAB of Boston Scientific, GSK, Halo Neuroscience, GSK, X and is inventor of brain stimulation patents and has grant support from NIH (MH111896, NS101362, NS112996). Colleen A. Hanlon has served as a consultant for Brainsway and receives grant support from the NIH (R01DA036617, R01DA044471, R01AA027705, R21DA044503). Adam J. Woods is a member of the scientific advisory board for Halo Neuroscience and has grant support from NIH (R01AG054077, R01AG064587, K01AG050707, R21MH112206, R37AG033906, RF1MH114290). Bernadette T. Gillick reports no conflict of interest and has current grant support from the NIH (R21HD097575), the National Center of Neuromodulation for Rehabilitation, and the Shepherd Trust/Jensen Family Award. Leigh Charvet has no conflict of interest and has current grant support from the NIH (R21NS101712), US Department of Defense (W81XWH-17-1-0320), National Multiple Sclerosis Society (RG-1803-30492) and the Lourie Foundation Inc. Adrienn Holczer reports no conflict of interest and is supported by the grant EFOP 3.6.3-VEKOP-16-2017-00009. Jorge Almeida has no conflict of interest and is supported by an ERC Starting Grant (Grant # 802553 - “ContentMAP”), and by grant PTDC/MHC-PCN/6805/2014 from Funda{\c c}{\~a}o para a Ci{\^e}ncia e a Tecnologia Portugal, and Programa COMPETE. Andrea Antal has received honoraria as speaker from NeuroCare (Munich, Germany) and as consultant from Savir GmbH (Magdeburg, Germany). Daniel M. Blumberger has received research support from Canadian Institutes for Health Research, National Institutes Health (US), Brain Canada and the Temerty Family through the CAMH Foundation and the Campbell Family Research Institute. He received research support and in-kind equipment support for an investigator-initiated study from Brainsway Ltd. He is the site principal investigator for three sponsor-initiated studies for Brainsway Ltd. He also receives in-kind equipment support from Magventure for investigator-initiated research. He received medication supplies for an investigator-initiated trial from Indivior. Joan A. Camprodon is a scientific advisor for Apex Neuroscience, has received royalties as book editor from Springer and has grant support from NIH (RO1 MH112737, R21 DA042271, R21 AG056958 and R21 MH115280). Colleen Loo has received royalties as book editor from Springer and has grant support from the Australian National Health and Medical Research Council. Jenny Crinion declares no conflict of interest and is supported by a Wellcome Trust Senior Research Fellowship in Clinical Science (106161/Z/14/Z). For this research as a part of Multidisciplinary Cognitive Rehabilitation (MCR) Platform, Iman Ghodratitoostani was supported (Grant number: 2013/07375-0) by Innovation and Diffusion of Mathematical Sciences Center Applied to Industry (CEPID-CeMEAI) of Sao Paulo Research Foundation (FAPESP), the University of Sao Paulo. Roland H. Grabner reports no conflict of interest and is supported by the Austrian Science Fund FWF (Grant P30050). Christian Ruff reports no conflict of interest and was supported by grants from the Swiss National Science Foundation SNSF (grant no. 100019L_173248) and from the European Research Council (ERC) under the European Union{\textquoteright}s Horizon 2020 research and innovation programme (grant agreement No 725355, ERC Consolidator BRAINCODES). Gottfried Schlaug has no conflict of interest and acknowledges support from the NIH (R01MH111874, U01NS102353). Hartwig R. Siebner has received honoraria as speaker from Sanofi Genzyme, Denmark and Novartis, Denmark, as consultant from Sanofi Genzyme, Denmark and as editor-in-chief (Neuroimage Clinical) and senior editor (NeuroImage) from Elsevier Publishers, Amsterdam, The Netherlands. He has received royalties as book editor from Springer Publishers, Stuttgart, Germany and from Gyldendal Publishers, Copenhagen, Denmark. Hartwig R. Siebner holds a 5-year professorship in precision medicine at the Faculty of Health Sciences and Medicine, University of Copenhagen which is sponsored by the Lundbeck Foundation (Grant Nr. R186-2015-2138). Xiaochu Zhang reports no conflict of interest and is supported by The National Key Basic Research Program (2016YFA0400900 and 2018YFC0831101), The National Natural Science Foundation of China (71942003, 31771221, 61773360, and 71874170). Hamed Ekhtiari reported no conflict of interest and is supported by grants from Brain and Behavior Foundation (NARSAD Young Investigator Award #27305) and Warren K. Family Foundation. Claus Lamm, Graziella Madeo, Mohammad Reza Ay, Chris Baeken, Salvatore Campanella, Lasse Christiansen, Paul Fitzgerald, Luigi Gallimberti, Peyman Ghobadi-Azbari, Gesa Hartwigsen, Akimasa Hirata, Adam Kirton, Helena Knotkova, Evgeny Krupitsky, Paola Marangolo, Ester M. Nakamura-Palacios, Weronika Potok, Samir K. Praharaj, Charlotte J. Stagg, Axel Thielscher, Nicole Wenderoth, and Ti-Fei Yuan report no conflict of interest or specific funding for this work. Funding Information: In most places across the world, neuromodulation studies have been suspended, yet the costs associated with those experiments (e.g. salaries, animal housing and food costs) have continued. This placed a financial burden on these studies and will also delay the final results of the studies. Thankfully, several funding agencies, including the US National Institute of Health, Wellcome Trust and the Medical Research Council UK, and Swiss National Science Foundation have announced the ability to apply for an Administrative or grant Supplement to cover unforeseen COVID-19-related costs. They have also streamlined the process for getting approval for a No Cost Extension. These steps offer significant relief to researchers and increase the likelihood that the dedicated resources already invested in these projects will be fruitful. Publisher Copyright: {\textcopyright} 2020 The Authors",

year = "2020",

month = may,

day = "16",

doi = "10.1016/j.brs.2020.05.010",

language = "English (US)",

volume = "13",

pages = "1124--1149",

journal = "Brain Stimulation",

issn = "1935-861X",

publisher = "Elsevier Inc.",

number = "4",

}

TY - JOUR

T1 - Guidelines for TMS/tES clinical services and research through the COVID-19 pandemic

AU - Bikson, Marom

AU - Hanlon, Colleen A.

AU - Woods, Adam J.

AU - Gillick, Bernadette T.

AU - Charvet, Leigh

AU - Lamm, Claus

AU - Madeo, Graziella

AU - Holczer, Adrienn

AU - Almeida, Jorge

AU - Antal, Andrea

AU - Ay, Mohammad Reza

AU - Baeken, Chris

AU - Blumberger, Daniel M.

AU - Campanella, Salvatore

AU - Camprodon, Joan A.

AU - Christiansen, Lasse

AU - Loo, Colleen

AU - Crinion, Jennifer T.

AU - Fitzgerald, Paul

AU - Gallimberti, Luigi

AU - Ghobadi-Azbari, Peyman

AU - Ghodratitoostani, Iman

AU - Grabner, Roland H.

AU - Hartwigsen, Gesa

AU - Hirata, Akimasa

AU - Kirton, Adam

AU - Knotkova, Helena

AU - Krupitsky, Evgeny

AU - Marangolo, Paola

AU - Nakamura-Palacios, Ester M.

AU - Potok, Weronika

AU - Praharaj, Samir K.

AU - Ruff, Christian C.

AU - Schlaug, Gottfried

AU - Siebner, Hartwig R.

AU - Stagg, Charlotte J.

AU - Thielscher, Axel

AU - Wenderoth, Nicole

AU - Yuan, Ti Fei

AU - Zhang, Xiaochu

AU - Ekhtiari, Hamed

N1 - Funding Information: Marom Bikson has equity on Soterix Medical, is consultant or SAB of Boston Scientific, GSK, Halo Neuroscience, GSK, X and is inventor of brain stimulation patents and has grant support from NIH (MH111896, NS101362, NS112996). Colleen A. Hanlon has served as a consultant for Brainsway and receives grant support from the NIH (R01DA036617, R01DA044471, R01AA027705, R21DA044503). Adam J. Woods is a member of the scientific advisory board for Halo Neuroscience and has grant support from NIH (R01AG054077, R01AG064587, K01AG050707, R21MH112206, R37AG033906, RF1MH114290). Bernadette T. Gillick reports no conflict of interest and has current grant support from the NIH (R21HD097575), the National Center of Neuromodulation for Rehabilitation, and the Shepherd Trust/Jensen Family Award. Leigh Charvet has no conflict of interest and has current grant support from the NIH (R21NS101712), US Department of Defense (W81XWH-17-1-0320), National Multiple Sclerosis Society (RG-1803-30492) and the Lourie Foundation Inc. Adrienn Holczer reports no conflict of interest and is supported by the grant EFOP 3.6.3-VEKOP-16-2017-00009. Jorge Almeida has no conflict of interest and is supported by an ERC Starting Grant (Grant # 802553 - “ContentMAP”), and by grant PTDC/MHC-PCN/6805/2014 from Fundação para a Ciência e a Tecnologia Portugal, and Programa COMPETE. Andrea Antal has received honoraria as speaker from NeuroCare (Munich, Germany) and as consultant from Savir GmbH (Magdeburg, Germany). Daniel M. Blumberger has received research support from Canadian Institutes for Health Research, National Institutes Health (US), Brain Canada and the Temerty Family through the CAMH Foundation and the Campbell Family Research Institute. He received research support and in-kind equipment support for an investigator-initiated study from Brainsway Ltd. He is the site principal investigator for three sponsor-initiated studies for Brainsway Ltd. He also receives in-kind equipment support from Magventure for investigator-initiated research. He received medication supplies for an investigator-initiated trial from Indivior. Joan A. Camprodon is a scientific advisor for Apex Neuroscience, has received royalties as book editor from Springer and has grant support from NIH (RO1 MH112737, R21 DA042271, R21 AG056958 and R21 MH115280). Colleen Loo has received royalties as book editor from Springer and has grant support from the Australian National Health and Medical Research Council. Jenny Crinion declares no conflict of interest and is supported by a Wellcome Trust Senior Research Fellowship in Clinical Science (106161/Z/14/Z). For this research as a part of Multidisciplinary Cognitive Rehabilitation (MCR) Platform, Iman Ghodratitoostani was supported (Grant number: 2013/07375-0) by Innovation and Diffusion of Mathematical Sciences Center Applied to Industry (CEPID-CeMEAI) of Sao Paulo Research Foundation (FAPESP), the University of Sao Paulo. Roland H. Grabner reports no conflict of interest and is supported by the Austrian Science Fund FWF (Grant P30050). Christian Ruff reports no conflict of interest and was supported by grants from the Swiss National Science Foundation SNSF (grant no. 100019L_173248) and from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme (grant agreement No 725355, ERC Consolidator BRAINCODES). Gottfried Schlaug has no conflict of interest and acknowledges support from the NIH (R01MH111874, U01NS102353). Hartwig R. Siebner has received honoraria as speaker from Sanofi Genzyme, Denmark and Novartis, Denmark, as consultant from Sanofi Genzyme, Denmark and as editor-in-chief (Neuroimage Clinical) and senior editor (NeuroImage) from Elsevier Publishers, Amsterdam, The Netherlands. He has received royalties as book editor from Springer Publishers, Stuttgart, Germany and from Gyldendal Publishers, Copenhagen, Denmark. Hartwig R. Siebner holds a 5-year professorship in precision medicine at the Faculty of Health Sciences and Medicine, University of Copenhagen which is sponsored by the Lundbeck Foundation (Grant Nr. R186-2015-2138). Xiaochu Zhang reports no conflict of interest and is supported by The National Key Basic Research Program (2016YFA0400900 and 2018YFC0831101), The National Natural Science Foundation of China (71942003, 31771221, 61773360, and 71874170). Hamed Ekhtiari reported no conflict of interest and is supported by grants from Brain and Behavior Foundation (NARSAD Young Investigator Award #27305) and Warren K. Family Foundation. Claus Lamm, Graziella Madeo, Mohammad Reza Ay, Chris Baeken, Salvatore Campanella, Lasse Christiansen, Paul Fitzgerald, Luigi Gallimberti, Peyman Ghobadi-Azbari, Gesa Hartwigsen, Akimasa Hirata, Adam Kirton, Helena Knotkova, Evgeny Krupitsky, Paola Marangolo, Ester M. Nakamura-Palacios, Weronika Potok, Samir K. Praharaj, Charlotte J. Stagg, Axel Thielscher, Nicole Wenderoth, and Ti-Fei Yuan report no conflict of interest or specific funding for this work. Funding Information: In most places across the world, neuromodulation studies have been suspended, yet the costs associated with those experiments (e.g. salaries, animal housing and food costs) have continued. This placed a financial burden on these studies and will also delay the final results of the studies. Thankfully, several funding agencies, including the US National Institute of Health, Wellcome Trust and the Medical Research Council UK, and Swiss National Science Foundation have announced the ability to apply for an Administrative or grant Supplement to cover unforeseen COVID-19-related costs. They have also streamlined the process for getting approval for a No Cost Extension. These steps offer significant relief to researchers and increase the likelihood that the dedicated resources already invested in these projects will be fruitful. Publisher Copyright: © 2020 The Authors

PY - 2020/5/16

Y1 - 2020/5/16

N2 - Background: The COVID-19 pandemic has broadly disrupted biomedical treatment and research including non-invasive brain stimulation (NIBS). Moreover, the rapid onset of societal disruption and evolving regulatory restrictions may not have allowed for systematic planning of how clinical and research work may continue throughout the pandemic or be restarted as restrictions are abated. The urgency to provide and develop NIBS as an intervention for diverse neurological and mental health indications, and as a catalyst of fundamental brain research, is not dampened by the parallel efforts to address the most life-threatening aspects of COVID-19; rather in many cases the need for NIBS is heightened including the potential to mitigate mental health consequences related to COVID-19. Objective: To facilitate the re-establishment of access to NIBS clinical services and research operations during the current COVID-19 pandemic and possible future outbreaks, we develop and discuss a framework for balancing the importance of NIBS operations with safety considerations, while addressing the needs of all stakeholders. We focus on Transcranial Magnetic Stimulation (TMS) and low intensity transcranial Electrical Stimulation (tES) - including transcranial Direct Current Stimulation (tDCS) and transcranial Alternating Current Stimulation (tACS). Methods: The present consensus paper provides guidelines and good practices for managing and reopening NIBS clinics and laboratories through the immediate and ongoing stages of COVID-19. The document reflects the analysis of experts with domain-relevant expertise spanning NIBS technology, clinical services, and basic and clinical research – with an international perspective. We outline regulatory aspects, human resources, NIBS optimization, as well as accommodations for specific demographics. Results: A model based on three phases (early COVID-19 impact, current practices, and future preparation) with an 11-step checklist (spanning removing or streamlining in-person protocols, incorporating telemedicine, and addressing COVID-19-associated adverse events) is proposed. Recommendations on implementing social distancing and sterilization of NIBS related equipment, specific considerations of COVID-19 positive populations including mental health comorbidities, as well as considerations regarding regulatory and human resource in the era of COVID-19 are outlined. We discuss COVID-19 considerations specifically for clinical (sub-)populations including pediatric, stroke, addiction, and the elderly. Numerous case-examples across the world are described. Conclusion: There is an evident, and in cases urgent, need to maintain NIBS operations through the COVID-19 pandemic, including anticipating future pandemic waves and addressing effects of COVID-19 on brain and mind. The proposed robust and structured strategy aims to address the current and anticipated future challenges while maintaining scientific rigor and managing risk.

AB - Background: The COVID-19 pandemic has broadly disrupted biomedical treatment and research including non-invasive brain stimulation (NIBS). Moreover, the rapid onset of societal disruption and evolving regulatory restrictions may not have allowed for systematic planning of how clinical and research work may continue throughout the pandemic or be restarted as restrictions are abated. The urgency to provide and develop NIBS as an intervention for diverse neurological and mental health indications, and as a catalyst of fundamental brain research, is not dampened by the parallel efforts to address the most life-threatening aspects of COVID-19; rather in many cases the need for NIBS is heightened including the potential to mitigate mental health consequences related to COVID-19. Objective: To facilitate the re-establishment of access to NIBS clinical services and research operations during the current COVID-19 pandemic and possible future outbreaks, we develop and discuss a framework for balancing the importance of NIBS operations with safety considerations, while addressing the needs of all stakeholders. We focus on Transcranial Magnetic Stimulation (TMS) and low intensity transcranial Electrical Stimulation (tES) - including transcranial Direct Current Stimulation (tDCS) and transcranial Alternating Current Stimulation (tACS). Methods: The present consensus paper provides guidelines and good practices for managing and reopening NIBS clinics and laboratories through the immediate and ongoing stages of COVID-19. The document reflects the analysis of experts with domain-relevant expertise spanning NIBS technology, clinical services, and basic and clinical research – with an international perspective. We outline regulatory aspects, human resources, NIBS optimization, as well as accommodations for specific demographics. Results: A model based on three phases (early COVID-19 impact, current practices, and future preparation) with an 11-step checklist (spanning removing or streamlining in-person protocols, incorporating telemedicine, and addressing COVID-19-associated adverse events) is proposed. Recommendations on implementing social distancing and sterilization of NIBS related equipment, specific considerations of COVID-19 positive populations including mental health comorbidities, as well as considerations regarding regulatory and human resource in the era of COVID-19 are outlined. We discuss COVID-19 considerations specifically for clinical (sub-)populations including pediatric, stroke, addiction, and the elderly. Numerous case-examples across the world are described. Conclusion: There is an evident, and in cases urgent, need to maintain NIBS operations through the COVID-19 pandemic, including anticipating future pandemic waves and addressing effects of COVID-19 on brain and mind. The proposed robust and structured strategy aims to address the current and anticipated future challenges while maintaining scientific rigor and managing risk.

KW - COVID-19

KW - Non-invasive brain stimulation

KW - Transcranial alternating current stimulation

KW - Transcranial direct current stimulation

KW - Transcranial electrical stimulation

KW - Transcranial magnetic stimulation

KW - Pandemics

KW - Humans

KW - Behavior, Addictive/therapy

KW - Coronavirus Infections/epidemiology

KW - SARS-CoV-2

KW - Pneumonia, Viral/epidemiology

KW - Stroke/therapy

KW - Betacoronavirus

KW - Child

KW - Transcranial Direct Current Stimulation/methods

KW - Brain/physiology

KW - Biomedical Research/methods

KW - Clinical Trials as Topic

KW - Transcranial Magnetic Stimulation/methods

KW - Nervous System Diseases/therapy

KW - Telemedicine/methods

KW - Delivery of Health Care/methods

KW - Substance-Related Disorders/therapy

KW - Aged

KW - Practice Guidelines as Topic

UR - http://www.scopus.com/inward/record.url?scp=85085039376&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85085039376&partnerID=8YFLogxK

U2 - 10.1016/j.brs.2020.05.010

DO - 10.1016/j.brs.2020.05.010

M3 - Article

C2 - 32413554

AN - SCOPUS:85085039376

SN - 1935-861X

VL - 13

SP - 1124

EP - 1149

JO - Brain Stimulation

JF - Brain Stimulation

IS - 4

ER -

Guidelines for TMS/tES clinical services and research through the COVID-19 pandemic

Abstract

Bibliographical note

Keywords

PubMed: MeSH publication types

UN SDGs

Publisher link

Find It

Other files and links

Fingerprint

Cite this